CN1455679A - Melagatran用于制备治疗局部缺血症的药物的用途 - Google Patents

Melagatran用于制备治疗局部缺血症的药物的用途 Download PDF

Info

Publication number
CN1455679A
CN1455679A CN00819999A CN00819999A CN1455679A CN 1455679 A CN1455679 A CN 1455679A CN 00819999 A CN00819999 A CN 00819999A CN 00819999 A CN00819999 A CN 00819999A CN 1455679 A CN1455679 A CN 1455679A
Authority
CN
China
Prior art keywords
melagatran
treatment
atrial fibrillation
patient
patients
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN00819999A
Other languages
English (en)
Chinese (zh)
Inventor
D·古斯塔夫松
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
AstraZeneca AB
Original Assignee
AstraZeneca AB
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by AstraZeneca AB filed Critical AstraZeneca AB
Publication of CN1455679A publication Critical patent/CN1455679A/zh
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/397—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having four-membered rings, e.g. azetidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
CN00819999A 2000-11-06 2000-11-09 Melagatran用于制备治疗局部缺血症的药物的用途 Pending CN1455679A (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US09/705,912 2000-11-06
US09/705,912 US6462021B1 (en) 2000-11-06 2000-11-06 Use of low molecular weight thrombin inhibitor

Publications (1)

Publication Number Publication Date
CN1455679A true CN1455679A (zh) 2003-11-12

Family

ID=24835453

Family Applications (1)

Application Number Title Priority Date Filing Date
CN00819999A Pending CN1455679A (zh) 2000-11-06 2000-11-09 Melagatran用于制备治疗局部缺血症的药物的用途

Country Status (14)

Country Link
US (1) US6462021B1 (enExample)
EP (1) EP1333855A1 (enExample)
JP (2) JP2004512376A (enExample)
KR (1) KR20040004431A (enExample)
CN (1) CN1455679A (enExample)
AU (2) AU2562501A (enExample)
BR (1) BR0017367A (enExample)
CA (1) CA2428012A1 (enExample)
IL (1) IL155431A0 (enExample)
MX (1) MXPA03003980A (enExample)
NO (1) NO20032006L (enExample)
NZ (1) NZ525487A (enExample)
WO (1) WO2002036157A1 (enExample)
ZA (1) ZA200303013B (enExample)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE9904377D0 (sv) * 1999-12-01 1999-12-01 Astra Pharma Prod Pharmaceutical combinations
SE0200198D0 (sv) 2002-01-23 2002-01-23 Astrazeneca Ab New use
SE0201373D0 (sv) * 2002-05-06 2002-05-06 Astrazeneca Ab Combination therapy
SE0201374D0 (sv) * 2002-05-06 2002-05-06 Astrazeneca Ab Pharmaceutical combination
DE60305113T2 (de) 2002-09-09 2006-12-07 Trigen Ltd. Borsäuresalze und deren Verwendung in der Bereitstellung von Medikamente für die Thrombosebehandlung
US7371729B2 (en) 2002-09-09 2008-05-13 Trigen Limited Boronic acid salts useful in parenteral formulations
GB0306615D0 (en) * 2003-03-22 2003-04-30 Astrazeneca Ab New use
AU2007276205A1 (en) * 2006-07-17 2008-01-24 Boehringer Ingelheim International Gmbh New indications for direct thrombin inhibitors in the cardiovascular field

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE9301916D0 (sv) 1993-06-03 1993-06-03 Ab Astra New peptides derivatives
SE504185C2 (sv) 1994-11-08 1996-12-02 Astra Ab Lagringsstabil vattenlösning för infusion av trombininhibitorer
SE9404196D0 (sv) 1994-12-02 1994-12-02 Astra Ab New antithrombotic formulation
JPH11514378A (ja) 1995-10-24 1999-12-07 メルク エンド カンパニー インコーポレーテッド トロンビン阻害剤
TWI238827B (en) 1995-12-21 2005-09-01 Astrazeneca Ab Prodrugs of thrombin inhibitors
SE9601556D0 (sv) 1996-04-24 1996-04-24 Astra Ab New pharmaceutical formulation of a thrombin inhibitor for parenteral use
SE9602145D0 (sv) 1996-05-31 1996-05-31 Astra Ab New improved formulation for treatment of thromboembolism
SE9603724D0 (sv) 1996-10-11 1996-10-11 Astra Ab New pharmaceutical parenteral formulation of a thrombin inhibitor
SE9704401D0 (sv) 1997-11-28 1997-11-28 Astra Ab Matrix pellets for greasy, oily or sticky drug substances
SE9704400D0 (sv) 1997-11-28 1997-11-28 Astra Ab Porous inorganic particles as carriers for drug substances
SE9802938D0 (sv) 1998-09-01 1998-09-01 Astra Ab Improved stability for injection solutions
SE9802973D0 (sv) 1998-09-03 1998-09-03 Astra Ab Immediate release tablet
SE9900070D0 (sv) 1999-01-13 1999-01-13 Astra Ab New use
AR023510A1 (es) * 1999-04-21 2002-09-04 Astrazeneca Ab Un equipo de partes, formulacion farmaceutica y uso de un inhibidor de trombina.

Also Published As

Publication number Publication date
US6462021B1 (en) 2002-10-08
NO20032006D0 (no) 2003-05-05
EP1333855A1 (en) 2003-08-13
NZ525487A (en) 2004-11-26
NO20032006L (no) 2003-07-01
BR0017367A (pt) 2003-10-07
AU2001225625B2 (en) 2006-06-15
WO2002036157A1 (en) 2002-05-10
CA2428012A1 (en) 2002-05-10
KR20040004431A (ko) 2004-01-13
JP2004512376A (ja) 2004-04-22
MXPA03003980A (es) 2003-08-19
ZA200303013B (en) 2004-07-16
IL155431A0 (en) 2003-11-23
JP2005120098A (ja) 2005-05-12
AU2562501A (en) 2002-05-15

Similar Documents

Publication Publication Date Title
JP4846063B2 (ja) 選択的ｓ１ｐ１レセプターアゴニストの投与法
JP5296557B2 (ja) 流涎症の治療のためのアルファ−２受容体アゴニスト（クロニジン）と抗ムスカリン剤（オキシブチニン）との組み合わせ
US10016397B2 (en) Selective AT2 receptor agonists for use in treatment of cachexia
EA020490B1 (ru) Способ лечения бактериальной инфекции
CN1512885A (zh) 药物组合
CN1402639A (zh) 药用组合物
CN1455679A (zh) Melagatran用于制备治疗局部缺血症的药物的用途
CN1170592C (zh) 美拉加林的新用途
CN100515421C (zh) 治疗剂及其制药用途
AU2001225625A1 (en) Use of melagatran for manufacture of a medicament for the treatment of ischemic disorders
KR20120089623A (ko) 정맥내 투여용 이부프로펜을 이용한 환자의 치료
KR20120138229A (ko) 정맥내 투여용 이부프로펜을 이용한 중증 환자의 치료
TW201500042A (zh) 與血液透析有關的低血壓的治療
NL2025730B1 (en) Compounds for treatment of sepsis
EP1553944B1 (fr) Composition pharmaceutique associant le tenatoprazole et un antagoniste des recepteurs h2 a l histamine
US20160166577A1 (en) Treatment of pulmonary fibrosis using an inhibitor of cbp/catenin
CN1354676A (zh) 用于心血管疾病疗法的氨基四氢化萘衍生物
CN1703234A (zh) 低分子量凝血酶抑制剂的新用途
JP3627801B2 (ja) 副鼻腔炎の予防および／または治療剤
IL320636A (en) Benzaldehyde compounds with destabilizing effects on polymers for the treatment of sickle cell disease
WO2025152110A1 (zh) 用于阿尔兹海默症治疗的联合用药及其药物组合物
CN114392257A (zh) 血竭素高氯酸盐的医药用途
JP2019182845A (ja) キヌレニンアミノトランスフェラーゼ２（ｋａｔ２）阻害剤
GRYGLEWSKI et al. who had been treated PGI2, 24 and 48 hours after occlusion of central
HK1036412B (en) Anti-inflammatory eye drops

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C02 Deemed withdrawal of patent application after publication (patent law 2001)
WD01 Invention patent application deemed withdrawn after publication

Open date: 20031112